NACT; neoadjuvant chemotherapy; pCR, pathological complete response; TNBC, triple-negative breast cancer; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; CPS-EG, clinical and pathologic stage and estrogen receptor status and histologic grade; ypN+, pathologically lymph node positive; iDFS, invasive disease-free survival; OS, overall survival. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.